AtriCure (ATRC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 May, 2026Opening remarks and agenda
Meeting conducted virtually to enable broad stockholder participation.
Agenda and rules of conduct were made available on the meeting website.
Stockholders could submit questions via the web portal, with follow-up promised for unanswered queries.
Board and executive committee updates
Introduction of all current board members present at the meeting.
Shareholder proposals
Election of nine directors for a one-year term.
Ratification of Deloitte as the independent registered public accounting firm for 2026.
Amendment to the 2023 Stock Incentive Plan to increase authorized shares by 1,500,000.
Amendment to the 2018 Employee Stock Purchase Plan to increase authorized shares by 750,000.
Advisory vote on executive compensation (say on pay) as required by Dodd-Frank.
Latest events from AtriCure
- Strong growth, innovation, and clinical trial catalysts drive robust financial and market expansion.ATRC
Canaccord Genuity's 46th Annual Growth Conference - Targeting $1B revenue by 2030, driven by innovation in Afib and pain management solutions.ATRC
Investor presentation - Q2 2026 revenue rose 12.8% to $153.6M, with net income of $9.0M and improved margins.ATRC
Q2 2026 - Targeting $1B revenue by 2030 through innovation, clinical data, and market expansion.ATRC
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - 2026 growth driven by innovation, exclusive clinical data, and expanding market opportunities.ATRC
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue rose 14.3% to $141.2M, with profitability and strong 2026 outlook.ATRC
Q1 2026 - Q2 2025 revenue up 17.1% year-over-year, with improved profitability and raised outlook.ATRC
Q2 2025 - Aiming for $1B+ revenue by 2030 through innovation and expanded clinical adoption.ATRC
Investor Day 2025 - Double-digit revenue and EBITDA growth in 2024, with robust 2025 outlook and product momentum.ATRC
Q4 2024